Skip to main content
Posted on 18 Sep 2024
Share news

Q&A in GEN with Natalia Elizalde

Natalia Elizalde, our Chief Business Development Officer at VIVEbiotech, recently shared her expertise with GEN on the increasing demand for lentiviral vectors, of which we are experts at VIVEbiotech.

Q&A in GEN with Natalia Elizalde

With the rise of innovative therapeutic modalities like CAR-Ts and vaccines, the need for efficient, purpose-built manufacturing technologies has never been greater.

Natalia highlighted how VIVEbiotech is incorporating cutting-edge solutions like AI and automation to enhance production efficiency and meet growing demand.

Don’t miss out on this insightful read: https://www.genengnews.com/topics/bioprocessing/vector-production-would-benefit-from-purpose-built-processing-technology/